[Immunonutrition].

Hideaki Saito

Home/Archive/PubMed

PubMed · 15027163

[Immunonutrition].

Hideaki Saito

View original source ↗Export metadata ↓

Abstract

Several specific nutritional substrates have been shown to augment and/or modulate host immune function. Some enteral formulas enriched with specific immune-modulating nutrients are presently available for clinical use in Japan. Such nutrients include n-3 fatty acids, arginine, glutamine and nucleotides. Recent meta-analyses of clinical trials showed risk of infection, length of hospital stay and medical costs to be reduced by immunonutrition. The benefits of enteral immunonutrition to be most pronounced in GI surgical patients. However, in critical illness, it is difficult to draw any conclusion on the effect of immunonutrition because of the heterogeneity of the critically ill patients and few clinical trials Further clinical trials to determine which groups of patients are indicated for immunonutrition, as well as what is the optimal combinations of specific nutrients, are needed. Studies are also required to determine the safety of immunonutrition.

Explore related subjects

Adjuvants, Immunologic Arginine Clinical Trials as Topic Fatty Acids, Omega-3 Glutamine Humans Meta-Analysis as Topic Nucleotides Nutritional Support Perioperative Care Surgical Procedures, Operative English Abstract Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Hideaki Saito. 2004. [Immunonutrition].. https://pubmed.ncbi.nlm.nih.gov/15027163/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients.

This pilot study was carried out to gain a first insight into the effects of peptide vaccination in melanoma patients in the high-risk adjuvant disease setting. From the adjuvant peptide vaccination studies carried out in our institution since 1998, we identified all melanoma patients with a history of at least 3 completely resected metastases during the year preceding enrollment into the trial and describe the clinical and immunologic observations. Out of a total of 44 patients with resected cutaneous melanoma entered into adjuvant peptide vaccination trials, 9 patients were identified with more than 3 metastases in the year before vaccination. After initiation of vaccination, 2 patients remained relapse-free for 27 and 42+ months, 2 patients experienced single or several initial relapses and subsequent relapse-free intervals of 18 and 65+ months, whereas 5 patients progressed. In both patients with relapse after prolonged relapse-free intervals, the relapses were initially confined to the small intestine and could be resected. Induction or boosting of functional tyrosinase peptide-specific T cells was noted in 6 of 8 patients, including all 4 patients with prolonged relapse-free intervals. In conclusion, adjuvant peptide vaccination was associated with cessation of recurrences in 4 of 9 patients, of whom all 4 had an immunologic response to the vaccine.

Adjuvants, Immunologic↗

PubMed2005

Serum antibody responses to equine herpesvirus 1 glycoprotein D in horses, pregnant mares and young foals.

The envelope glycoprotein D of equine herpesvirus 1 (EHV-1 gD) has been shown in laboratory animal models to elicit protective immune responses against EHV-1 challenge, and hence is a potential vaccine antigen. Here we report that intramuscular inoculation of EHV-1 gD produced by a recombinant baculovirus and formulated with the adjuvant Iscomatrix elicited virus-neutralizing antibody and gD-specific ELISA antibody in the serum of over 90% of adult mixed breed horses. The virus-neutralizing antibody responses to EHV-1 gD were similar to those observed after inoculation with a commercially available killed EHV-1/4 whole virus vaccine. Intramuscular inoculation of EHV-1 gD DNA encoded in a mammalian expression vector was less effective in inducing antibody responses when administered as the sole immunogen, but inoculation with EHV-1 gD DNA followed by recombinant EHV-1 gD induced increased gD ELISA and virus-neutralizing antibody titres in six out of seven horses. However, these titres were not higher than those induced by either EHV-1 gD or the whole virus vaccine. Isotype analysis revealed elevated gD-specific equine IgGa and IgGb relative to IgGc, IgG(T) and IgA in horses inoculated with EHV-1 gD or with the whole virus vaccine. Following inoculation of pregnant mares with EHV-1 gD, their foals had significantly higher levels of colostrally derived anti-gD antibody than foals out of uninoculated mares. The EHV-1 gD preparation did not induce a significant mean antibody response in neonatal foals following inoculation at 12 h post-partum and at 30 days of age, irrespective of the antibody status of the mare. The ability of EHV-1 gD to evoke comparable neutralizing antibody responses in horses to those of a whole virus vaccine confirms EHV-1 gD as a promising candidate for inclusion in subunit vaccines against EHV-1.

Adjuvants, Immunologic↗

PubMed2005

A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant.

A dose escalating, placebo-controlled phase 1 trial was conducted to test the safety and immunogenicity of a vaccine containing recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1) formulated in Montanide ISA720. Three groups of volunteers were vaccinated intramuscularly with 5 microg, 20 microg or 80 microg of AMA1, respectively, in 0.5 mL of formulation at 0, 3 and 6 months. Anti-AMA1 antibody levels and T cell stimulation indices were measured before and after each vaccination. No vaccine-related serious adverse events were recorded. Most subjects generated a mild to moderate, transient local reaction after the first vaccination. Three subjects developed a local reaction approximately 10 days following vaccination. Six of the 29 subjects seroconverted. Only one of these developed a high antibody titre. However, the interpretation of this trial was compromised by a loss of potency of the formulated vaccine during the course of the study.

Adjuvants, Immunologic↗